Biofrontera Gelecekteki Büyüme

Future kriter kontrolleri 5/6

Biofrontera is forecast to grow earnings and revenue by 70.6% and 22% per annum respectively while EPS is expected to grow by 74.5% per annum.

Anahtar bilgiler

70.6%

Kazanç büyüme oranı

74.5%

EPS büyüme oranı

Pharmaceuticals kazanç büyümesi23.7%
Gelir büyüme oranı22.0%
Gelecekteki özkaynak getirisin/a
Analist kapsamı

Low

Son güncelleme31 Oct 2024

Gelecekteki son büyüme güncellemeleri

Recent updates

Biofrontera Inc.'s (NASDAQ:BFRI) Shares Leap 25% Yet They're Still Not Telling The Full Story

Sep 28
Biofrontera Inc.'s (NASDAQ:BFRI) Shares Leap 25% Yet They're Still Not Telling The Full Story

Further Upside For Biofrontera Inc. (NASDAQ:BFRI) Shares Could Introduce Price Risks After 40% Bounce

Aug 09
Further Upside For Biofrontera Inc. (NASDAQ:BFRI) Shares Could Introduce Price Risks After 40% Bounce

Take Care Before Jumping Onto Biofrontera Inc. (NASDAQ:BFRI) Even Though It's 29% Cheaper

May 24
Take Care Before Jumping Onto Biofrontera Inc. (NASDAQ:BFRI) Even Though It's 29% Cheaper

Biofrontera Inc. (NASDAQ:BFRI) Not Doing Enough For Some Investors As Its Shares Slump 28%

Dec 30
Biofrontera Inc. (NASDAQ:BFRI) Not Doing Enough For Some Investors As Its Shares Slump 28%

The Market Doesn't Like What It Sees From Biofrontera Inc.'s (NASDAQ:BFRI) Revenues Yet As Shares Tumble 43%

Nov 13
The Market Doesn't Like What It Sees From Biofrontera Inc.'s (NASDAQ:BFRI) Revenues Yet As Shares Tumble 43%

Can Biofrontera (NASDAQ:BFRI) Afford To Invest In Growth?

Oct 18
Can Biofrontera (NASDAQ:BFRI) Afford To Invest In Growth?

Biofrontera announces preliminary Q3 product revenue, stock falls ~7% after hours

Oct 05

Biofrontera gets notice of allowance for U.S. patent covering a nanoemulsion formulation

Sep 06

Biofrontera GAAP EPS of -$0.05, revenue of $4.5M; reaffirms FY22 guidance

Aug 12

Biofrontera announces 2Q prelim product revenues

Jul 12

Kazanç ve Gelir Büyüme Tahminleri

NasdaqCM:BFRI - Analistlerin gelecek tahminleri ve geçmiş finansal verileri (USD Millions )
TarihGelirKazançlarSerbest Nakit AkışıFaaliyetlerden NakitAvg. Analist Sayısı
12/31/2026601N/AN/A1
12/31/202548-5N/A-62
12/31/202440-15N/A-112
6/30/202435-14-19-19N/A
3/31/202433-23-25-25N/A
12/31/202334-20-25-25N/A
9/30/202334-26-24-24N/A
6/30/202329-23-28-28N/A
3/31/202328-14-18-18N/A
12/31/202229-1-16-16N/A
9/30/202228-12-29-29N/A
6/30/202228-26-24-24N/A
3/31/202229-29-25-25N/A
12/31/202124-38-27-27N/A
9/30/202124-23-6-6N/A
6/30/202122-10-6-6N/A
3/31/202119-10-9-9N/A
12/31/202019-11-12-12N/A
12/31/201926-11-38-38N/A

Analist Gelecek Büyüme Tahminleri

Kazançlar ve Tasarruf Oranları: BFRI is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2.5%).

Kazançlar ve Piyasa: BFRI is forecast to become profitable over the next 3 years, which is considered above average market growth.

Yüksek Büyüme Kazançları: BFRI is expected to become profitable in the next 3 years.

Gelir ve Pazar: BFRI's revenue (22% per year) is forecast to grow faster than the US market (8.9% per year).

Yüksek Büyüme Geliri: BFRI's revenue (22% per year) is forecast to grow faster than 20% per year.


Hisse Başına Kazanç Büyüme Tahminleri


Gelecekteki Özkaynak Getirisi

Gelecekteki ROE: Insufficient data to determine if BFRI's Return on Equity is forecast to be high in 3 years time


Büyüyen şirketleri keşfedin